Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 125

1.

Medication use and associated health care outcomes and costs for patients with psoriasis in the United States.

Lin HC, Lucas PT, Feldman SR, Balkrishnan R.

J Dermatolog Treat. 2012 Jun;23(3):196-202. doi: 10.3109/09546634.2010.544708. Epub 2011 Jan 22.

PMID:
21254887
2.

Medication-related factors affecting health care outcomes and costs for patients with psoriasis in the United States.

Kulkarni AS, Balkrishnan R, Richmond D, Pearce DJ, Feldman SR.

J Am Acad Dermatol. 2005 Jan;52(1):27-31.

PMID:
15627077
3.

Medication choice and associated health care outcomes and costs for patients with acne and acne-related conditions in the United States.

Patel P, Lin HC, Feldman SR, Fleischer AB Jr, Nahata MC, Balkrishnan R.

J Drugs Dermatol. 2011 Jul;10(7):766-71.

PMID:
21720659
4.
5.

Economic and Comorbidity Burden Among Patients with Moderate-to-Severe Psoriasis.

Feldman SR, Zhao Y, Shi L, Tran MH.

J Manag Care Spec Pharm. 2015 Oct;21(10):874-88.

6.

Prior authorization for topical psoriasis treatments: is it cost-beneficial for managed care?

Balkrishnan R, Bhosle MJ, Fleischer AB Jr, Feldman SR.

J Dermatolog Treat. 2010 May;21(3):178-84. doi: 10.3109/09546630903268247.

PMID:
19821787
7.

A retrospective cohort study of the impact of biologic therapy initiation on medical resource use and costs in patients with moderate to severe psoriasis.

Fonia A, Jackson K, Lereun C, Grant DM, Barker JN, Smith CH.

Br J Dermatol. 2010 Oct;163(4):807-16. doi: 10.1111/j.1365-2133.2010.09944.x. Erratum in: Br J Dermatol. 2012 Jun;166(6):1381. Br J Dermatol. 2014 Jan;170(1):226.

PMID:
20662837
8.

Cost-of-illness in patients with moderate and severe chronic psoriasis vulgaris in Germany.

Berger K, Ehlken B, Kugland B, Augustin M.

J Dtsch Dermatol Ges. 2005 Jul;3(7):511-8.

PMID:
15967010
9.

The burden of illness associated with psoriasis: cost of treatment with systemic therapy and phototherapy in the US.

Crown WH, Bresnahan BW, Orsini LS, Kennedy S, Leonardi C.

Curr Med Res Opin. 2004 Dec;20(12):1929-36.

PMID:
15701211
10.

Predictors of healthcare outcomes and costs related to medication use in patients with acne in the United States.

Balkrishnan R, Kulkarni AS, Cayce K, Feldman SR.

Cutis. 2006 Apr;77(4):251-5.

PMID:
16706243
11.
13.

Processes of psoriasis health care in Germany--long-term analysis of data from the statutory health insurances.

Augustin M, Glaeske G, Schäfer I, Rustenbach SJ, Hoer A, Radtke MA.

J Dtsch Dermatol Ges. 2012 Sep;10(9):648-55. doi: 10.1111/j.1610-0387.2012.07893.x. Epub 2012 Apr 23. English, German.

PMID:
22525221
14.

Costs of Common Psoriasis Medications, 2010-2014.

James SM, Hill DE, Feldman SR.

J Drugs Dermatol. 2016 Mar;15(3):305-8.

PMID:
26954315
15.

Utilization pattern of etanercept and its cost implications in moderate to severe psoriasis in a managed care population.

Wu EQ, Feldman SR, Chen L, Kaltenboeck A, Yu AP, Gupta SR, Laitinen D, Willian MK.

Curr Med Res Opin. 2008 Dec;24(12):3493-501. doi: 10.1185/03007990802551057 .

PMID:
19032131
16.

Psoriasis treatment in the United States at the end of the 20th century.

Pearce DJ, Stealey KH, Balkrishnan R, Fleischer AB Jr, Feldman SR.

Int J Dermatol. 2006 Apr;45(4):370-4.

PMID:
16650160
17.

Medication adherence and health care costs associated with biologics in Medicaid-enrolled patients with psoriasis.

Bhosle MJ, Feldman SR, Camacho FT, Timothy Whitmire J, Nahata MC, Balkrishnan R.

J Dermatolog Treat. 2006;17(5):294-301.

PMID:
17092860
18.

Costs associated with attempted suicide among individuals with bipolar disorder.

Stensland MD, Zhu B, Ascher-Svanum H, Ball DE.

J Ment Health Policy Econ. 2010 Jun;13(2):87-92.

PMID:
20919595
19.

Health economic analyses of psoriasis management: a systematic literature search.

Gutknecht M, Krensel M, Augustin M.

Arch Dermatol Res. 2016 Nov;308(9):601-616. Epub 2016 Jul 19. Review.

PMID:
27435415

Supplemental Content

Support Center